Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 103 recruiting now full pipeline #30 of 28,963 conditions

Type 2 Diabetes: full-pipeline trial registry

103 of 289 indexed Type 2 Diabetes trials are currently recruiting.

Corpus placement: #30 of 28,963 conditions by registered trial count.

289 US clinical trials · 103 currently recruiting · #30 of 28,963 conditions by registered trial count

Type 2 Diabetes: 289 US clinical trials tracked, 103 recruiting.

Type 2 Diabetes is the subject of 289 registered US clinical trials on ClinicalTrials.gov, 103 of them currently open to new participants. 56 are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 20 of these trials.

Open enrollment snapshot

Type 2 Diabetes has 289 registered US clinical trials, 103 of them open to new participants right now, about 36% of the total.

103
recruiting participants now
36%
of trials open to enrollment
56
in Phase 3-4 (later-stage)
20
top sponsor: Eli Lilly and Company

Corpus placement: #30 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Type 2 Diabetes on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Type 2 Diabetes recruits in line with its size-band peers.

    103 of 289 indexed trials (35.6%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Type 2 Diabetes trials is spread across many organizations.

    Eli Lilly and Company accounts for 20 of 289 trials (6.9%). 140 distinct sponsors appear on at least one study for this condition label.

  3. Typical Type 2 Diabetes enrolment sits around 96 participants.

    Median target enrolment is 96 among the 289 trials that report a genuine target (sentinel values excluded). 145 of those (50.2%) plan for fewer than 100 participants.

  4. Type 2 Diabetes research is mostly interventional.

    257 interventional and 32 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 121Phase 221Phase 334Phase 422

Open and recent trials

289 total, page 3 of 6

RECRUITING NA 12 participants

Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis

AdventHealth Translational Research Institute

NCT06993454

RECRUITING Early Phase 1 10 participants

Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

The University of Texas Health Science Center at San Antonio

NCT06108076

RECRUITING NA 10 participants

Brown Adipose Tissue Activation by Spinal Cord Stimulation

Oregon Health and Science University

NCT04326192

ACTIVE NOT RECRUITING 70,000 participants

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Brigham and Women's Hospital

NCT06779929

ACTIVE NOT RECRUITING 60,000 participants

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

Brigham and Women's Hospital

NCT07417618

ACTIVE NOT RECRUITING 30,000 participants

Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.

Brigham and Women's Hospital

NCT07417631

ACTIVE NOT RECRUITING 26,000 participants

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

Brigham and Women's Hospital

NCT06980623

ACTIVE NOT RECRUITING 25,664 participants

Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)

Brigham and Women's Hospital

NCT07390110

ACTIVE NOT RECRUITING Phase 3 2,749 participants

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Eli Lilly and Company

NCT05803421

ACTIVE NOT RECRUITING 1,035 participants

SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy

Kaiser Permanente

NCT01967030

ACTIVE NOT RECRUITING NA 1,017 participants

Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS

Massachusetts General Hospital

NCT02087826

ACTIVE NOT RECRUITING Phase 3 1,000 participants

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Novo Nordisk A/S

NCT06221969

ACTIVE NOT RECRUITING Phase 3 1,000 participants

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Eli Lilly and Company

NCT05929079

ACTIVE NOT RECRUITING Phase 4 780 participants

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Eli Lilly and Company

NCT05433584

ACTIVE NOT RECRUITING Phase 2 600 participants

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

NCT07033585

ACTIVE NOT RECRUITING NA 450 participants

Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1

State University of New York at Buffalo

NCT04203173

ACTIVE NOT RECRUITING Phase 2 414 participants

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Eli Lilly and Company

NCT06037252

ACTIVE NOT RECRUITING Phase 3 330 participants

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Novo Nordisk A/S

NCT07220759

ACTIVE NOT RECRUITING Phase 3 320 participants

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Eli Lilly and Company

NCT06297603

ACTIVE NOT RECRUITING NA 300 participants

Innovative Automated Insulin Delivery System for Type 2 Diabetes

Deka Research and Development

NCT06853990

ACTIVE NOT RECRUITING NA 300 participants

Lowering the Impact of Food Insecurity in African American Adults With Type 2 Diabetes Mellitus (LIFT-DM)

State University of New York at Buffalo

NCT04181424

ACTIVE NOT RECRUITING NA 294 participants

Personalized Dietary Management in Type 2 Diabetes

NYU Langone Health

NCT05046886

ACTIVE NOT RECRUITING NA 291 participants

Diabetes Medical Nutrition Therapy in Southeastern African American Women

Meharry Medical College

NCT04971889

ACTIVE NOT RECRUITING NA 284 participants

Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans

University of Texas at Austin

NCT04282395

ACTIVE NOT RECRUITING Phase 2 221 participants

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Zealand Pharma

NCT06926842

ACTIVE NOT RECRUITING NA 162 participants

Together Overcoming Diabetes

Johns Hopkins Bloomberg School of Public Health

NCT04734015

ACTIVE NOT RECRUITING NA 150 participants

The Hope App Study

See Yourself Health

NCT05729516

ACTIVE NOT RECRUITING NA 150 participants

Randomized Controlled Trial of Digital Twin Precision Treatment: A Novel Whole Body Digital Twin Enabled Precision Treatment for Type 2 Diabetes

The Cleveland Clinic

NCT05181449

ACTIVE NOT RECRUITING NA 150 participants

E3 Diabetes - Closing the Gap in Diabetes Control

Rush University Medical Center

NCT06643936

ACTIVE NOT RECRUITING Phase 2 140 participants

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Eli Lilly and Company

NCT05536804

ACTIVE NOT RECRUITING NA 132 participants

Preventing Diabetes in Latino Families

Arizona State University

NCT05228522

ACTIVE NOT RECRUITING NA 127 participants

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

Foundation for Atlanta Veterans Education and Research

NCT05040087

ACTIVE NOT RECRUITING NA 120 participants

Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes

Charles Drew University of Medicine and Science

NCT05765214

ACTIVE NOT RECRUITING NA 117 participants

Group Versus Traditional Prenatal Care for Diabetes

Washington University School of Medicine

NCT03301792

ACTIVE NOT RECRUITING NA 108 participants

Continuous Glucose Monitoring Following Hospital Discharge

Kathleen Dungan

NCT05360056

ACTIVE NOT RECRUITING Phase 3 100 participants

Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

University of Alabama at Birmingham

NCT05098470

ACTIVE NOT RECRUITING NA 100 participants

Conditional Cash Transfer Intervention to Improve T2DM

State University of New York at Buffalo

NCT05559892

ACTIVE NOT RECRUITING NA 84 participants

Exercise Resistance in Type 2 Diabetes

AdventHealth Translational Research Institute

NCT01911104

ACTIVE NOT RECRUITING 80 participants

Glycemic Control, Type II Diabetes, Parathyroidectomy

The Cleveland Clinic

NCT05761743

ACTIVE NOT RECRUITING NA 67 participants

Diabetes Nutrition Education and Healthy Food Resource for AIANs With T2D

Colorado State University

NCT06077162

ACTIVE NOT RECRUITING NA 60 participants

Recreational Basketball to Increase Participation in Diabetes Prevention

Kaiser Permanente

NCT05066542

ACTIVE NOT RECRUITING Phase 2 50 participants

The Medically Reproducing Bariatric Surgery (MRB) II Study

Durham VA Medical Center

NCT06363747

ACTIVE NOT RECRUITING NA 45 participants

Understanding and Optimizing Care for Young Adults With Type 1 and Type 2 Diabetes Mellitus Transitioning to Adult Care

Massachusetts General Hospital

NCT05229718

ACTIVE NOT RECRUITING Phase 4 43 participants

DIALYSIS-TIR Study

University of Texas Southwestern Medical Center

NCT06042153

ACTIVE NOT RECRUITING NA 30 participants

Application of Time Restriction Feeding in Patients With Type 2 Diabetes Mellitus

OhioHealth

NCT05015504

ACTIVE NOT RECRUITING Phase 4 30 participants

Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion

Mayo Clinic

NCT05264727

ACTIVE NOT RECRUITING NA 20 participants

Continuous Glucose Monitoring System Feasibility in Youth With T2D

University of California, San Francisco

NCT06089070

ACTIVE NOT RECRUITING NA 20 participants

Multilevel Lifestyle Intervention to Improve Physical Function in Older Adults With Type 2 Diabetes

The University of Texas Health Science Center at San Antonio

NCT06173804

ACTIVE NOT RECRUITING Phase 1 14 participants

Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment

NYU Langone Health

NCT05601583

ACTIVE NOT RECRUITING NA 12 participants

Daily Protein Pacing Effects on HbA1c in Type 2 Diabetics

Skidmore College

NCT05355090

← Previous Page 3 of 6 Next →

Phase Distribution

PhaseTrial count
Phase 1 21
Phase 2 21
Phase 3 34
Phase 4 22

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Type 2 Diabetes right now

103 recruiting of 289 indexed (36% open).

Phase mix: 56 late (III/IV) vs 42 early (I/II) (balanced across stages).

Top sponsor: Eli Lilly and Company (20 trials), 9 others listed. 50 shown below, recruiting first. #30 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Type 2 Diabetes?

PlainTrial tracks 289 US clinical trials for Type 2 Diabetes, of which 103 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Type 2 Diabetes?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.